Abstract
Neoadjuvant endocrine therapy improves surgical outcomes for postmenopausal women with bulky hormone receptor-positive breast cancer. Recent studies indicate that this approach may also be used in the management of smaller tumors with the hope of predicting outcomes from adjuvant endocrine manipulation. Neoadjuvant endocrine therapy provides a unique opportunity to identify molecular predictors of endocrine responsiveness and agents that can be used in combination with endocrine therapy to improve tumor response and overcome endocrine resistance.
Original language | English |
---|---|
Pages (from-to) | 627-638 |
Number of pages | 12 |
Journal | Surgical Oncology Clinics of North America |
Volume | 19 |
Issue number | 3 |
DOIs | |
State | Published - Jul 2010 |
Keywords
- Breast cancer
- Estrogen receptor
- Genomics
- Neoadjuvant endocrine therapy
- Relapse risk